유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장 규모는 향후 수년간 급성장 될 예정입니다. 성장은 AAV 캡시드 엔지니어링의 지속적인 발전, 정밀의료에 대한 중점 증가, 유전자 연구 및 생명 공학 투자 증가, 유전자 치료 임상 검사 및 규제 승인 급증, 개인 맞춤형 치료 접근법에 대한 수요 증가에 기인할 수 있습니다. 이 기간에 예상되는 주요 동향은 AAV 캡시드 설계에서 인공지능의 통합, 보다 큰 유전자 페이로드를 운반할 수 있는 하이브리드 AAV 벡터의 개발, 이중 특이성 항체를 통한 AAV 타겟팅의 혁신, 확장 가능한 AAV 제조 및 정제 방법의 진보, 다양한 바이러스 벡터 용도를 지원합니다.
유전자 기반 치료가 중요해지면 유전자 치료용 AAV(아데노 부속 바이러스) 벡터의 성장이 촉진 될 것으로 예측됩니다. 유전자 기반 치료법은 분자 수준에서 질병을 예방, 치료 또는 치료하기 위해 유전자를 수정하거나 조작하는 것을 포함합니다. 유전자 연구 개발은 유전자 편집 기술의 정확성과 효능을 향상시킴으로써 이러한 치료법의 개발에 박차를 가하고 있습니다. AAV 벡터는 낮은 면역원성과 장기 유전자 발현 능력 덕분에 표적 세포에 치료 유전자를 안전하고 효율적으로 전달함으로써 유전자 치료에서 중요한 역할을 합니다. 2023년 미국 생명과학 산업을 위한 분석 및 기술 솔루션 제공업체인 IQVIA는 세포 및 유전자 치료에 대한 전 세계 지출이 59억 달러에 달했으며, 이는 2022년에 비해 38% 증가한 수치라고 보고했습니다. 그 결과, 유전자에 의한 치료에 대한 주목의 고조가 AAV 벡터 시장의 확대에 기여하고 있습니다.
유전자 치료용 AAV(아데노 부속 바이러스) 벡터 부문에 관여하는 기업은 분석의 다양성을 높이기 위한 벡터 다양성의 도입 등 기술 혁신에 주력하고 있습니다. 이 전략은 조직 특이성, 치료 효과를 향상시키고 다양한 조건에서 맞춤형 유전자 치료법 개발을 지원합니다. 벡터의 다양성은 다양한 AAV 혈청형과 구조를 사용하여 다양한 분석 절차와 치료 응용을 지원하는 것입니다. 예를 들어, 2024년 5월, 미국에 본사를 둔 제약 회사인 찰스 리버 래버러토리스는 아데노 관련 바이러스(AAV)와 렌티바이러스 벡터(LVV)에 대한 새로운 참고 자료를 출시했습니다. 이 재료들은 세포 및 유전자 치료(CGT) 개발의 증가하는 요구를 충족시키기 위해 설계되었으며, 초기 연구에서 GMP 등급 제조로의 전환을 촉진합니다. 이번 출시는 제조 공정를 표준화해, 바이러스 벡터 제조의 일관성을 향상시키는 것을 목적으로 하고 있어, CGT 프로그램을 임상 및 상업 단계로 진행시키는데 있어 주요 과제를 해결하는 것을 목표로 합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장 : 성장률 분석
- 세계의 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장 실적: 규모와 성장, 2019-2024년
- 세계의 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장 예측 : 규모와 성장, 2024-2029년, 2034년
- 세계 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장 : 치료 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 유전자 증강
- 면역요법
- 기타 유형의 치료법
- 세계의 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장 : 사용 유전자 전달 방법 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- Ex Vivo
- In Vivo
- 세계의 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장 : 사업 규모별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 전임상
- 임상
- 수술
- 세계의 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장 : 대상 치료 영역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 유전성 질환
- 혈액 질환
- 감염증
- 대사 장애
- 안질환
- 근육장애
- 신경질환
- 기타 대상 치료 영역
- 세계의 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장 : 유전자 증강별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 단일 유전자 질환
- 신경질환
- 근육질환
- 안과 질환
- 대사 장애
- 세계의 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장 : 면역요법별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 종양학
- 감염증
- 자가면역질환
- 백신 개발
- T세포공학
- 세계의 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장 : 기타 유형 치료법별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 유전자 편집 지원
- RNA 간섭
- 신경보호와 신경재생
- 항염증 용도
- 재생 의료
제7장 지역별/국가별 분석
- 세계의 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 세계의 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장 : 경쟁 구도
- 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장 : 기업 프로파일
- F. Hoffmann-La Roche Ltd.
- Sanofi SA
- Novartis AG
- Astellas Gene Therapies Inc.
- Biogen Inc.
제31장 기타 주요 기업 및 혁신 기업
- Sarepta Therapeutics Inc.
- Oxford BioMedica plc
- Rocket Pharmaceuticals Inc.
- Aldevron LLC
- REGENXBIO Inc.
- uniQure NV
- Passage Bio Inc.
- Voyager Therapeutics Inc.
- Dyno Therapeutics Inc.
- MeiraGTx Holdings plc
- Abeona Therapeutics Inc.
- 4D Molecular Therapeutics Inc.
- GenSight Biologics SA
- Taysha Gene Therapies Inc.
- LogicBio Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 전략
- 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장, 2029년 : 새로운 기회를 제공하는 국가
- 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장, 2029년 : 새로운 기회를 제공하는 부문
- 유전자 치료용 AAV(아데노 부속 바이러스) 벡터 시장, 2029년 : 성장 전략
제36장 부록
SHW
Adeno-associated virus (AAV) vectors are advanced gene therapy delivery systems designed to transport genetic material into cells for the treatment of various genetic conditions. Their main objective is to provide targeted and long-lasting therapeutic outcomes by repairing or modifying defective genes. AAV vectors are highly regarded for their safety profile, minimal immune response, and ability to deliver genes to both dividing and non-dividing cells, thereby supporting the creation of precise and lasting gene therapies that enhance personalized medicine and revolutionize the management of rare and inherited diseases.
The primary categories of adeno-associated virus (AAV) vectors include gene augmentation, immunotherapy, and other therapeutic approaches. Gene augmentation involves introducing a functional gene into a cell to replace or supplement a missing or defective one. This can be achieved through various delivery techniques, such as ex vivo and in vivo methods. These therapies are developed and applied at multiple operational stages, including preclinical, clinical, and commercial levels. The targeted therapeutic areas encompass genetic disorders, blood-related diseases, infectious illnesses, metabolic conditions, eye disorders, muscular diseases, and neurological disorders.
The adeno-associated virus (AVV) vectors in gene therapy market research report is one of a series of new reports from The Business Research Company that provides adeno-associated virus (AVV) vectors in gene therapy market statistics, including precision weight industry global market size, regional shares, competitors with an adeno-associated virus (AVV) vectors in gene therapy market share, precision weight market segments, market trends, and opportunities, and any further data you may need to thrive in the adeno-associated virus (AVV) vectors in gene therapy industry. This adeno-associated virus (AVV) vectors in gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The adeno-associated virus (AVV) vectors in gene therapy market size has grown rapidly in recent years. It will grow from $2.70 billion in 2024 to $3.18 billion in 2025 at a compound annual growth rate (CAGR) of 17.7%. The growth during the historic period can be credited to greater investment in gene therapy research, the growing use of gene editing technologies, an increase in genetic disorders and unmet medical needs, rising demand for targeted treatments, and enhanced collaboration between biotechnology companies and research organizations.
The adeno-associated virus (AVV) vectors in gene therapy market size is expected to see rapid growth in the next few years. It will grow to $6.09 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The anticipated growth in the forecast period can be attributed to ongoing advancements in AAV capsid engineering, a heightened emphasis on precision medicine, increasing investments in genetic research and biotechnology, a surge in gene therapy clinical trials and regulatory approvals, and a growing demand for personalized treatment approaches. Key trends expected during this period include the integration of artificial intelligence in AAV capsid design, the development of hybrid AAV vectors capable of carrying larger genetic payloads, innovations in bispecific antibody-mediated AAV targeting, progress in scalable AAV manufacturing and purification methods, and the creation of adaptable AAV platforms that support a variety of viral vector applications.
The rising emphasis on gene-based therapies is expected to drive the growth of the adeno-associated virus (AAV) vectors in the gene therapy market. Gene-based therapies involve the modification or manipulation of genes to prevent, treat, or cure diseases at the molecular level. Advances in genetic research are fueling the development of these therapies by improving the precision and effectiveness of gene editing techniques. AAV vectors play a key role in gene therapy by safely and efficiently delivering therapeutic genes into target cells, thanks to their low immunogenicity and capacity for long-term gene expression. For example, in 2023, IQVIA, a U.S.-based provider of analytics and technology solutions for the life sciences industry, reported that global spending on cell and gene therapies reached $5.9 billion, a 38% increase compared to 2022. As a result, the growing focus on gene-based therapies is contributing to the expansion of the AAV vectors market.
Companies involved in the AAV vectors segment of the gene therapy market are concentrating on technological innovation, such as introducing tailored vector diversity for assay versatility. This strategy enhances tissue specificity, therapeutic effectiveness, and supports the development of customized gene therapies for a range of conditions. Tailored vector diversity refers to the use of various AAV serotypes or constructs to support different analytical procedures and therapeutic applications. For instance, in May 2024, Charles River Laboratories, a U.S.-based pharmaceutical company, launched new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). These materials are designed to meet the growing demands of cell and gene therapy (CGT) development, facilitating the transition from early research to GMP-grade manufacturing. The launch aims to standardize production processes and improve consistency in viral vector manufacturing, addressing a major challenge in advancing CGT programs toward clinical and commercial stages.
In March 2023, Ginkgo Bioworks, a U.S.-based biotechnology company, acquired assets related to StrideBio's AAV capsid discovery and engineering platform for an undisclosed amount. This acquisition is intended to strengthen Ginkgo Bioworks' research and development capabilities in gene therapy, with a focus on creating novel adeno-associated virus (AAV) capsids to enhance gene delivery. StrideBio is a U.S.-based biotech company specializing in the development of engineered AAV capsids for use in gene therapy applications.
Major players in the adeno-associated virus (avv) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.
North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2024. The regions covered in adeno-associated virus (AAV) vectors in gene therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the adeno-associated virus (AAV) vectors in gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The adeno-associated virus (AAV) vectors in gene therapy market consists of revenues earned by entities by providing services such as gene delivery solutions, targeted therapeutic development, long-term gene expression, and treatment of genetic disorders through safe and efficient viral vector technologies. The market value includes the value of related goods sold by the service provider or included within the service offering. The adeno-associated virus (AAV) vectors in gene therapy market includes sales of viral vector delivery systems used for transporting genetic material into patient cells. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Adeno-Associated Virus (AVV) Vectors In Gene Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on adeno-associated virus (avv) vectors in gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for adeno-associated virus (avv) vectors in gene therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adeno-associated virus (avv) vectors in gene therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type of Therapy: Gene Augmentation; Immunotherapy; Other Type of Therapy
- 2) By Type of Gene Delivery Method Used: Ex Vivo; In Vivo
- 3) By Scale of Operation: Preclinical; Clinical; Commercial
- 4) By Target Therapeutic Area: Genetic Disorders; Hematological Disorders; Infectious Diseases; Metabolic Disorders; Ophthalmic Disorders; Muscle Disorders; Neurological Disorders; Other Target Therapeutic Area
- Subsegments:
- 1) By Gene Augmentation: Monogenic Disorders; Neurological Disorders; Muscular Disorders; Ophthalmological Disorders; Metabolic Disorders
- 2) By Immunotherapy: Oncology; Infectious Diseases; Autoimmune Disorders; Vaccine Development; T-Cell Engineering
- 3) By Other Type of Therapy: Gene Editing Support; RNA Interference; Neuroprotection and Neuroregeneration; Anti-Inflammatory Applications; Regenerative Medicine
- Companies Mentioned: F. Hoffmann-La Roche Ltd.; Sanofi S.A.; Novartis AG; Astellas Gene Therapies Inc.; Biogen Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Characteristics
3. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Trends And Strategies
4. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Growth Analysis And Strategic Analysis Framework
- 5.1. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth Rate Analysis
- 5.4. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Total Addressable Market (TAM)
6. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Segmentation
- 6.1. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Gene Augmentation
- Immunotherapy
- Other Type Of Therapy
- 6.2. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Ex Vivo
- In Vivo
- 6.3. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Preclinical
- Clinical
- Commercial
- 6.4. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Genetic Disorders
- Hematological Disorders
- Infectious Diseases
- Metabolic Disorders
- Ophthalmic Disorders
- Muscle Disorders
- Neurological Disorders
- Other Target Therapeutic Area
- 6.5. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Sub-Segmentation Of Gene Augmentation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monogenic Disorders
- Neurological Disorders
- Muscular Disorders
- Ophthalmological Disorders
- Metabolic Disorders
- 6.6. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oncology
- Infectious Diseases
- Autoimmune Disorders
- Vaccine Development
- T-Cell Engineering
- 6.7. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Sub-Segmentation Of Other Type of Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Gene Editing Support
- RNA Interference
- Neuroprotection and Neuroregeneration
- Anti-Inflammatory Applications
- Regenerative Medicine
7. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Regional And Country Analysis
- 7.1. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 8.1. Asia-Pacific Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 9.1. China Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
- 9.2. China Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 10.1. India Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 11.1. Japan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
- 11.2. Japan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 12.1. Australia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 13.1. Indonesia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 14.1. South Korea Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
- 14.2. South Korea Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 15.1. Western Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
- 15.2. Western Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 16.1. UK Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 17.1. Germany Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 18.1. France Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 19.1. Italy Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 20.1. Spain Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 21.1. Eastern Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
- 21.2. Eastern Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 22.1. Russia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 23.1. North America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
- 23.2. North America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 24.1. USA Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
- 24.2. USA Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 25.1. Canada Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
- 25.2. Canada Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 26.1. South America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
- 26.2. South America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 27.1. Brazil Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 28.1. Middle East Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
- 28.2. Middle East Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
- 29.1. Africa Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
- 29.2. Africa Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Competitive Landscape And Company Profiles
- 30.1. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Competitive Landscape
- 30.2. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Astellas Gene Therapies Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Other Major And Innovative Companies
- 31.1. Sarepta Therapeutics Inc.
- 31.2. Oxford BioMedica plc
- 31.3. Rocket Pharmaceuticals Inc.
- 31.4. Aldevron LLC
- 31.5. REGENXBIO Inc.
- 31.6. uniQure N.V.
- 31.7. Passage Bio Inc.
- 31.8. Voyager Therapeutics Inc.
- 31.9. Dyno Therapeutics Inc.
- 31.10. MeiraGTx Holdings plc
- 31.11. Abeona Therapeutics Inc.
- 31.12. 4D Molecular Therapeutics Inc.
- 31.13. GenSight Biologics S.A.
- 31.14. Taysha Gene Therapies Inc.
- 31.15. LogicBio Therapeutics Inc.
32. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
34. Recent Developments In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market
35. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market High Potential Countries, Segments and Strategies
- 35.1 Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
